Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-Mediated Protein Degradation

Time: 9:00 am
day: Day Two


  • With a significant proportion of the intracellular proteome likely being amenable to PROTAC-mediated degradation, considerable focus needs to be placed on identifying the best therapeutic opportunities for this technology
  • This presentation will share some experiences at GSK assessing different targets and the consideration of whether a PROTAC approach represented the modality of choice
  • Data will be presented highlighting how factors such as protein synthesis rates, the relationship between the extent of degradation and functional response as well as additional pharmacology that cannot be accessed via an inhibitor can impact this assessment